


AVE-0118

Cat. No.:	HY-118387
CAS No.:	498577-53-0
Molecular Formula:	C ₃₀ H ₂₉ N ₃ O ₃
Molecular Weight:	479.57
Target:	Potassium Channel
Pathway:	Membrane Transporter/Ion Channel
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	AVE-0118 is a nonselective Kv1.5 blocker with an IC ₅₀ of 1.1 μM. AVE-0118 is a multichannel inhibitor with weak, micromolar activity against Kv1.5 and other ion channels. It is inactive against I _{Ks} , I _{KATP} , and L-type Ca ⁺ channels ^[1] .
IC₅₀ & Target	IC ₅₀ : 1.1 μM (Kv1.5), 3.4 μM (I _{to}), 4.5 μM (I _{KAch}), 8.4 μM (I _{Kr}) ^[1]
In Vitro	AVE-0118 is shown to be a Kv1.5 blocker (IC ₅₀ = 1.1 μM) with moderate selectivity versus I _{to} (3.4 μM), I _{Kr} (8.4 μM), and I _{KAch} (4.5 μM) and good selectivity versus I _{Ks} , I _{K1} , I _{KATP} ^[1] . AVE-0118 (10 μM) significantly potentiates the electrical field stimulation (EFS)-induced neurogenic type of contractions ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	AVE-0118 reduces the inducibility of AF in goats with remodeled atria at a dose of 3 mg/kg and did not prolong QTc up to 5 mg/kg ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Bilodeau MT, et al. Kv1.5 blockers for the treatment of atrial fibrillation: approaches to optimization of potency and selectivity and translation to in vivo pharmacology. *Curr Top Med Chem*. 2009;9(5):436-51.

[2]. Kun A, et al. Neurogenic contraction induced by the antiarrhythmic compound, AVE 0118, in rat small mesenteric arteries. *Basic Clin Pharmacol Toxicol*. 2014 Oct;115(4):315-20.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA